SONNEVELD, P., Roman HÁJEK, A NAGLER, A SPENCER, J BLADÉ, T ROBAK, SH ZHUANG, JL HAROUSSEAU and R ORLOWSKI. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer. United States: Wiley, 2008, vol. 112, No 7, p. 1529-1537. ISSN 0008-543X. |
Other formats:
BibTeX
LaTeX
RIS
@article{817666, author = {Sonneveld, P. and Hájek, Roman and Nagler, A and Spencer, A and Bladé, J and Robak, T and Zhuang, SH and Harousseau, JL and Orlowski, R}, article_location = {United States}, article_number = {7}, keywords = {multiple myeloma;doxorubicin;bortezomib}, language = {eng}, issn = {0008-543X}, journal = {Cancer}, title = {Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.}, volume = {112}, year = {2008} }
TY - JOUR ID - 817666 AU - Sonneveld, P. - Hájek, Roman - Nagler, A - Spencer, A - Bladé, J - Robak, T - Zhuang, SH - Harousseau, JL - Orlowski, R PY - 2008 TI - Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. JF - Cancer VL - 112 IS - 7 SP - 1529-1537 EP - 1529-1537 PB - Wiley SN - 0008543X KW - multiple myeloma;doxorubicin;bortezomib N2 - Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma. (MM). In the current analysis, they determined 1) the efficacy of PLD plus bortezomib versus bortezomib alone in patients with MM who had failed on prior thalidomide/lenalidomide (immunomodulatory drug [IMiD]) treatment and 2) the efficacy and safety profile of PLD plus bortezomib in IMiD-exposed and IMiD-naive patients. ER -
SONNEVELD, P., Roman HÁJEK, A NAGLER, A SPENCER, J BLADÉ, T ROBAK, SH ZHUANG, JL HAROUSSEAU and R ORLOWSKI. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. \textit{Cancer}. United States: Wiley, 2008, vol.~112, No~7, p.~1529-1537. ISSN~0008-543X.
|